A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A major new study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards vulnerable infants
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild cold-like symptoms to causing severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine operates by activating the mother’s immune system to generate defence proteins, which are then passed to the foetus through the placenta. This maternal immunity offers newborns with instant defence from the point of delivery, precisely when they are most vulnerable to RSV. The new study shows that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still deliver meaningful protection, with evidence indicating that a two-week gap is adequate to shield babies delivered prematurely. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst noting that protection remains possible even if administered later in the third trimester.
- Nearly 85% coverage when vaccinated 4 weeks before birth
- Maternal antibodies passed through placenta protect newborns from birth
- Coverage achievable with two-week gap before premature birth
- Vaccination during third trimester still offers meaningful infant protection
Strong evidence from current research
The performance of the pregnancy RSV vaccine has been established through a thorough investigation undertaken in England, examining data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately nine out of ten of all births during that six-month period, providing strong and reliable information of the vaccine’s real-world impact. The study’s conclusions have been supported by the UK Health Security Agency as showing strong protection for newborns during their most vulnerable early months. The scope of this study provides healthcare professionals and parents-to-be with trust in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.
The results present a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were treated in hospital with RSV during the study period, with the overwhelming majority being infants whose mothers did not receive the vaccination. This marked difference highlights the vaccine’s essential role in protecting against serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms associated with severe RSV infection. These findings strengthen the importance of the vaccination programme established in the UK in 2024.
Research approach and coverage
The research analysed birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine clear comparisons of RSV infection rates and hospitalisations. The substantial sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to determine the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology captured practical outcomes rather than experimental conditions, providing real-world data of how the vaccine functions when given across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the dangers
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to severe, life-threatening chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.
The infection produces deep inflammation in the lungs and airways, making it dangerously difficult for affected infants to feed and breathe adequately. Parents often witness their babies struggling visibly, their chests rising whilst they attempt to draw sufficient oxygen into their compromised lungs. Whilst most infants get better with supportive care, a small but significant group succumb from RSV complications each year, making immunisation programmes a critical public health imperative for defending the youngest and most vulnerable individuals in the population.
- RSV produces lung inflammation, resulting in severe breathing difficulties in babies
- Nearly 50% of infants contract the infection in their first few months of life
- Symptoms range from mild colds to life-threatening chest infections needing hospital treatment
- Over 20,000 UK infants need serious hospital treatment for RSV annually
- Small numbers of infants die from RSV related complications each year in the UK
Adoption rates and specialist advice
Since the RSV vaccine programme launched in 2024, health officials have stressed the value of pregnant women receiving their jab at the optimal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for ensuring newborns receive the maximum immunity from birth. Whilst the research shows that vaccination at least four weeks before delivery offers nearly 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to maximise the antibodies passed to their babies via the placenta.
The guidance from public health bodies stays clear: pregnant women should prioritise vaccination during their final three months, even if circumstances mean they cannot receive the jab at the ideal window. Dr Watson has provided reassurance to expectant mothers that protection remains still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This adaptable strategy acknowledges the practical demands of pregnancy whilst maintaining strong protection for at-risk infants during their most critical early months when RSV represents the highest danger of serious illness.
Regional differences in immunisation
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Some areas have attained greater immunisation rates among qualifying expectant mothers, whilst others remain focused to boost understanding and availability of the jab. These regional differences demonstrate variations in medical facilities, communication strategies, and local engagement efforts, though the overall statistics demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts rolling out varied communication campaigns to reach women during pregnancy
- Inconsistencies across regions in vaccination coverage levels in different parts of England require targeted improvement
- Local healthcare systems adapting programmes to meet local requirements and situations
Practical implications and parent viewpoints
The vaccine’s impressive effectiveness delivers real advantages for families throughout the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the introduction of this safeguarding intervention, the 80% reduction in admissions means thousands of infants protected against critical disease. Parents no longer face the upsetting situation of seeing their babies labour to breathe or difficulty feeding, symptoms that define serious RSV disease. The vaccine has fundamentally shifted the landscape of neonatal respiratory health, offering expectant mothers a proactive tool to protect their youngest infants during those vital initial period.
For families like that of Malachi, whose severe RSV infection led to profound brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s promotion of the jab emphasises the transformative consequences that vaccine-preventable disease can cause to young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such grave complications—hospitalisation, oxygen dependency, neurological damage—are now largely preventable has offered substantial reassurance to pregnant women during their late pregnancy, transforming what was once an unavoidable seasonal threat into a manageable health risk.